AstraZeneca sells cholesterol drug rights to Grünenthal for $320 million

AstraZeneca sells cholesterol drug rights to Grünenthal for $320 million AstraZeneca, which is among the front-runners in the race to develop a vaccine for the novel coronavirus, has been trying to focus on its cancer drug portfolio as it streamlines its business.

No comments:

Post a Comment